A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia (CELIA)
What is this Study about?
This Phase 2 study aims to study to evaluate the efficacy and safety of study treatment in paticipants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia
What Will Happen in This Study?
Participants will receive study treatment or placebo administered as intrathecal (IT) injection every 12 weeks for up to 72 weeks.
Who is Eligible to Participate in this Study?
Age 50 - 80
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
Any materials or links provided herein are strictly for informational purposes only. The Alzheimer Society of Canada does not endorse nor recommend any of the manufacturers, products or institutions mentioned in any of these links or listings as suitable or appropriate for your particular situation or circumstances and disclaims any liability with respect to representations, warranties, including fitness for an intended particular use or purpose, and all other claims relating thereto, all of which remain strictly with the manufacturer or institution.
In no event shall the Alzheimer Society of Canada or any third parties mentioned on the website be liable for any damage (including, without limitation, incidental and consequential damages for personal injury/wrongful death, lost profits or damages resulting from lost data or business interruption) or personal injury (including death) resulting from the use, misuse or inability to use any activity, product or service mentioned herein, whether based in warranty, contract, tort or any other legal theory.
Everyone considering participating in any activity is encouraged to speak with their own doctor or health-care team before participating in any activity that may impact their health or well-being.